Location: Online, Virtual
Date: May 15 to May 17
The American College of Cardiology’s 70th Annual Scientific Session
Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in medicare and veteran affairs
Prof. Deitelzweig shares us some of his recent research on health economics and outcomes research on real world data.
PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol
Dr. Geeta Gulati, Dr. Siri Lagethon Heck and Prof. Torbjorn Omland presenting the new result from PRADA Trial.
ADAPTABLE Study: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
Prof. William Schuyler Jones speaks about the results of the ADAPTABLE Study.
PARADISE-MI: Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction
Prof. Marc Pfeffer presenting the new result from PARADISE-MI.
Inspiration-S Double Blind Randomized Controlled Trial: Atorvastatin Versus Placebo In Critically-ill Patients With Covid-19
Dr. Behnood Bikdeli speaks about his study, that looked at statins from a diffrent direction, even as a preventive way.
Core Knowledge in Action: The Ultimate Guide to Lipids
Prof. Eugene Yang, the chair of the ACC cardiovascular disease session share with us some guidance and principles from the recent ACC 2021 session that focuses on the ultimate guide to lipids.
Evolocumab use in patients with human immunodeficiency virus and dyslipidemia
Franck Boccara speaks about his study, the efficacy and tolerability of evolocumab a new PCSK9 inhibitors in specific populations such as the HIV population.
Tailor-Pci Randomized Clinical Trial Follow-up Study: Effect Of Genotype-guided Oral P2y12 Inhibitors Vs Conventional Clopidogrel On Long-term Ischemic Outcomes After Percutaneous Coronary Intervention
Prof. Naveen L. Pereira speaks about how we can individualize, personalize cardiology treatment.
Results From the Twilight Study: Sex-Specific Outcomes In High-Risk Patients Receiving Ticagrelor With Or Without Aspirin After Percutaneous Coronary Intervention
Dr. Birgit Vogel speaks about the newest findings of the Twilight Study.
VOYAGER PAD Trial: Reductions In Total Ischemic Events With Rivaroxaban In Patients With Symptomatic Pad After Revascularization
Prof. Rupert Bauersachs speaks about the newest findings of the VOYAGER PAD Trial.
Aspirin Vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention
Prof. Hyo-Soo Kim summarized the most important findings of the trial.
Effects Of Interleukin-6 Inhibition With Ziltivekimab On Biomarkers Of Inflammation Among Patients At High Risk For Atherosclerotic Events
Professor Paul M. Ridker summarize what we learned about the connection between inflammation and atherosclerosis in the last couple of years.
ISCHEMIA Trial: Impact Of Completeness Of Revascularization On Clinical Outcomes In Patients With Stable Ischemic Heart Disease Treated With An Invasive Vs. Conservative Strategy
Prof. Gregg Stone summarize the findings of ISCHEMIA Trial.
A Phase 2 Trial Of The Efficacy And Safety Of Evinacumab In Patients With Severe Hypertriglyceridemia
Prof. Robert Rosenson summarize the main findings of the trial.
Hypertension Guidelines: Do They Vary Across the World as Much as My Blood Pressure Has Today?
Prof. Paul Whelton speaks about the newest guidelines in the treatment of Hypertension.
STRENGTH Trial: Relationship Between Omega-3 Fatty Acid Levels And Major Adverse Cardiovascular Outcomes In Patients With High Cardiovascular Risk
Prof. Steven E. Nissen summarize the main findings of the STRENGTH Trial.